Skip to main content

Table 2 Main outcomes measures in control and intervention groups cluster level summaries

From: Effectiveness and safety of misoprostol distributed to antenatal women to prevent postpartum haemorrhage after child-births: a stepped-wedge cluster-randomized trial

Outcome Control group (n=6) Intervention group (n=6) Risk differencec (Control-intervention) (95 % CI) p-value
Primary outcome
 PPH Hb diffa ≥2g/dl (sd) 18.5 % (5.9) 11.4 % (8.4) 7.1 % (-3.1 % to 17.3 %) 0.14
 PPH Hb diffb ≥2g/dl (sd) 15.0 % (4.3) 11.1 % (3.0) 3.9 % (-1.5 % to 9.3 %) 0.12
Secondary outcomes
 Postpartum anaemia (sd) 43.3 % (10.0) 41.3 % (11.0) 2.0 % (-2.4 % to 6.4 %) 0.30
 Health facility births (sd) 87.5 % (7.3) 85.4 % (9.3) 2.1 % (-1.4 % to 5.6 %) 0.19
 Uterotonic use at birth (sd) 80.4 % (12.6) 91.4 % (7.0) −11.0 % (-25.7 % to 3.6 %) 0.11
 Fever & shivering (sd) 14.9 % (3.4) 22.2 % (5.3) −7.2 % (-11.1 % to -3.7 %) 0.005
  1. PPH postpartum haemorrhage, aHb diff=postpartum haemoglobin - antenatal haemoglobin in women followed within 3rd to 5th day; n=412 in control and n=377 in intervention, bHb difference in all women; n=1140 in control and n=909 in intervention, c risk difference at cluster level are in means, sd standard deviation, CI confidence interval